Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy

Carmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carmen D Zorrilla, Vivian Tamayo-Agrait
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/476c9066c288485b8edd744f252507d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:476c9066c288485b8edd744f252507d0
record_format	dspace
spelling	oai:doaj.org-article:476c9066c288485b8edd744f252507d02021-12-02T10:39:17ZPharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy1179-1373https://doaj.org/article/476c9066c288485b8edd744f252507d02009-12-01T00:00:00Zhttp://www.dovepress.com/pharmacologic-and-nonpharmacologic-options-for-the-management-of-hiv-i-a3808https://doaj.org/toc/1179-1373Carmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both pharmacologic and nonpharmacologic strategies to prevent mother-to-child transmission (MTCT). Optimal prevention of the MTCT of HIV requires antiretroviral drugs (ARV) during pregnancy, during labor, and to the infant. ARVs reduce viral replication, lowering maternal plasma viral load and thus the likelihood of MTCT. Postexposure prophylaxis of ARV agents in newborns protect against infection following potential exposure to maternal HIV during birth. In general, the choice of an ARV for treatment of HIV-infected women during pregnancy is complicated by the need to consider the effectiveness of the therapy for the maternal disease as well as the teratogenic or teratotoxic potential of these drugs. Clinicians managing HIV in pregnancy need to discuss the potential risks and benefits of available therapy options so that mothers can make informed decisions in choosing the best treatment regimen for themselves and for their children.Keywords: HIV, pregnancy, acquired immunodeficiency syndrome, antiretroviral agents Carmen D ZorrillaVivian Tamayo-AgraitDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2009, Iss Default, Pp 41-53 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Carmen D Zorrilla Vivian Tamayo-Agrait Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
description	Carmen D Zorrilla, Vivian Tamayo-AgraitDepartment of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, Maternal Infant Studies Center (CEMI), San Juan, Puerto RicoAbstract: Over the past decade, significant advances have been made in the treatment of HIV-1 infection using both pharmacologic and nonpharmacologic strategies to prevent mother-to-child transmission (MTCT). Optimal prevention of the MTCT of HIV requires antiretroviral drugs (ARV) during pregnancy, during labor, and to the infant. ARVs reduce viral replication, lowering maternal plasma viral load and thus the likelihood of MTCT. Postexposure prophylaxis of ARV agents in newborns protect against infection following potential exposure to maternal HIV during birth. In general, the choice of an ARV for treatment of HIV-infected women during pregnancy is complicated by the need to consider the effectiveness of the therapy for the maternal disease as well as the teratogenic or teratotoxic potential of these drugs. Clinicians managing HIV in pregnancy need to discuss the potential risks and benefits of available therapy options so that mothers can make informed decisions in choosing the best treatment regimen for themselves and for their children.Keywords: HIV, pregnancy, acquired immunodeficiency syndrome, antiretroviral agents
format	article
author	Carmen D Zorrilla Vivian Tamayo-Agrait
author_facet	Carmen D Zorrilla Vivian Tamayo-Agrait
author_sort	Carmen D Zorrilla
title	Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
title_short	Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
title_full	Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
title_fullStr	Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
title_full_unstemmed	Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy
title_sort	pharmacologic and nonpharmacologic options for the management of hiv infection during pregnancy
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/476c9066c288485b8edd744f252507d0
work_keys_str_mv	AT carmendzorrilla pharmacologicandnonpharmacologicoptionsforthemanagementofhivinfectionduringpregnancy AT viviantamayoagrait pharmacologicandnonpharmacologicoptionsforthemanagementofhivinfectionduringpregnancy
_version_	1718396872481046528

Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy

Ejemplares similares